Belite Bio, Inc
BLTE
Cena:
$ 137.30
-6.95 (-4.82%)
Valuace
70
Růst
0
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
BELITE BIO ANNOUNCES PRICING OF $350.0 MILLION UNDERWRITTEN PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES
01-12-2025
SAN DIEGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (“BELITE BIO” OR THE...
Více zde
BELITE BIO ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES
01-12-2025
SAN DIEGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (“BELITE BIO” OR TH...
Více zde
NEW HOPE FOR PEOPLE LIVING WITH A DISEASE ONCE DEEMED UNTREATABLE: BELITE BIO ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PIVOTAL GLOBAL, PHASE 3 DRAGON TRIAL OF TINLAREBANT IN ADOLESCENTS WITH STARGARDT DISEASE
01-12-2025
SAN DIEGO, DEC. 01, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (“BELITE BIO” OR THE...
Více zde
BELITE BIO TO PRESENT AT THE DBVIC - DEUTSCHE BANK ADR VIRTUAL INVESTOR CONFERENCE NOVEMBER 4TH
29-10-2025
COMPANY INVITES INDIVIDUAL AND INSTITUTIONAL INVESTORS, AS WELL AS ADVISORS AND ANALYSTS, TO ATTEND ...
Více zde
BELITE BIO TO PARTICIPATE IN THE DEUTSCHE BANK ADR VIRTUAL INVESTOR CONFERENCE
29-10-2025
SAN DIEGO, OCT. 29, 2025 (GLOBE NEWSWIRE) -- BELITE BIO INC (NASDAQ: BLTE) (“BELITE” OR THE “...
Více zde
BELITE BIO ANNOUNCES CHINA NMPA AGREES TO NEW DRUG APPLICATION WITH PRIORITY REVIEW BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT
15-10-2025
SAN DIEGO, OCT. 15, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), A CLINICAL-STAGE DRUG ...
Více zde
BELITE BIO ANNOUNCES UP TO $275 MILLION UPSIZED PRIVATE PLACEMENT FINANCING BY LEADING HEALTHCARE INVESTORS
08-09-2025
SAN DIEGO, SEPT. 08, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC ("BELITE BIO" OR THE "COMPANY") (NASDA...
Více zde
BELITE BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
11-08-2025
SAN DIEGO, AUG. 11, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE DRUG...
Více zde
BELITE BIO ANNOUNCES REGISTERED DIRECT OFFERING OF $15 MILLION
07-08-2025
SAN DIEGO, AUG. 07, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC ("BLTE" OR THE "COMPANY") (NASDAQ: BLTE...
Více zde
BELITE BIO ANNOUNCES COMPLETION OF ENROLLMENT IN THE PIVOTAL GLOBAL PHASE 3 PHOENIX TRIAL EVALUATING ORAL TINLAREBANT IN GEOGRAPHIC ATROPHY
02-07-2025
- 500 SUBJECTS ENROLLED ACROSS THE UNITED STATES, THE UNITED KINGDOM, FRANCE, CZECH REPUBLIC, SWIT...
Více zde
BELITE BIO ANNOUNCES FDA GRANTING OF BREAKTHROUGH THERAPY DESIGNATION FOR TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE
21-05-2025
SAN DIEGO, MAY 21, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHA...
Více zde
BELITE BIO REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
13-05-2025
SAN DIEGO, MAY 13, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHAR...
Více zde
BELITE BIO, INC TO PRESENT AT THE DBVIC - DEUTSCHE BANK ADR VIRTUAL INVESTOR CONFERENCE MAY 15TH
12-05-2025
COMPANY INVITES INDIVIDUAL AND INSTITUTIONAL INVESTORS, AS WELL AS ADVISORS AND ANALYSTS, TO ATTEND ...
Více zde
BELITE BIO TO PARTICIPATE IN FOUR UPCOMING INVESTOR CONFERENCES
12-05-2025
SAN DIEGO, MAY 12, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHAR...
Více zde
BELITE BIO REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
17-03-2025
SAN DIEGO, MARCH 17, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOP...
Více zde
BELITE BIO TO HOST WEBCAST ON MARCH 17, 2025, TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
11-03-2025
SAN DIEGO, MARCH 11, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOPH...
Více zde
BELITE BIO ANNOUNCES REGISTERED DIRECT OFFERING OF $15 MILLION
05-02-2025
SAN DIEGO, FEB. 05, 2025 (GLOBE NEWSWIRE) -- BELITE BIO, INC ("BLTE" OR THE "COMPANY") (NASDAQ: BLTE...
Více zde
LIN BIOSCIENCE RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR LBS-007
27-11-2024
TAIPEI CITY, TAIWAN, NOV. 27, 2024 (GLOBE NEWSWIRE) -- LIN BIOSCIENCE (6696. TAIWAN OTC), A CLINICAL...
Více zde
BELITE BIO TO HOST WEBCAST ON NOVEMBER 12, 2024, TO DISCUSS THIRD QUARTER 2024 FINANCIAL RESULTS
05-11-2024
SAN DIEGO, NOV. 05, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHA...
Více zde
BELITE BIO ANNOUNCES EXERCISE OF WARRANTS FOR US$28.75 MILLION GROSS PROCEEDS
03-11-2024
SAN DIEGO, NOV. 03, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (“BELITE BIO” OR TH...
Více zde
BELITE BIO ANNOUNCES APPOINTMENT OF HENDRIK P. N. SCHOLL, MD, MA, AS CHIEF MEDICAL OFFICER
01-09-2024
SAN DIEGO, SEPT. 01, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (“BELITE BIO” OR TH...
Více zde
BELITE BIO REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
09-08-2024
SAN DIEGO, AUG. 09, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (“BELITE” OR THE “...
Více zde
BELITE BIO TO PRESENT AT THE H.C. WAINWRIGHT 4TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE
08-08-2024
SAN DIEGO, AUG. 08, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), A CLINICAL-STAGE BIOPH...
Více zde
BELITE BIO TO HOST WEBCAST ON AUGUST 12, 2024, TO DISCUSS SECOND QUARTER 2024 FINANCIAL RESULTS
05-08-2024
SAN DIEGO, AUG. 05, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHA...
Více zde
BELITE BIO RECEIVES SAKIGAKE (PIONEER DRUG) DESIGNATION OF TINLAREBANT FOR STARGARDT DISEASE IN JAPAN
12-06-2024
SAN DIEGO, JUNE 12, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (“BELITE BIO” OR THE...
Více zde
BELITE BIO TO PARTICIPATE IN THE BENCHMARK'S 4TH ANNUAL HEALTHCARE HOUSE CALL INVESTOR CONFERENCE
14-05-2024
SAN DIEGO, MAY 14, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHA...
Více zde
BELITE BIO REPORTS FIRST-QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
13-05-2024
SAN DIEGO, MAY 13, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (“BELITE” OR THE “C...
Více zde
BELITE BIO TO PARTICIPATE IN THE H.C. WAINWRIGHT 2ND ANNUAL BIOCONNECT INVESTOR CONFERENCE
13-05-2024
SAN DIEGO, MAY 13, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHA...
Více zde
BELITE BIO TO HOST WEBCAST ON MAY 14, 2024, TO DISCUSS FIRST QUARTER 2024 FINANCIAL RESULTS
08-05-2024
SAN DIEGO, MAY 08, 2024 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE), A CLINICAL-STAGE BIOPHAR...
Více zde
BELITE BIO TO PARTICIPATE IN KEY OPINION LEADER WEBINAR TO DISCUSS UNMET NEEDS IN STARGARDT DISEASE (STGD1) AND GEOGRAPHIC ATROPHY (GA) AND PERSPECTIVES ON TINLAREBANT
06-05-2024
WEBINAR, MODERATED BY CANTOR FITZGERALD, WILL BE HELD ON MONDAY, MAY 13, 2024, AT 2:00 P.M. ET DISCU...
Více zde
Dokumenty nejsou k dispozici
